Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.494 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease | Dr. WONG Raymond Siu Ming |
| 2022.411 | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2011.284 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Prof. Chan Lik Yuen Henry |
| 2011.180 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Dr Hui Aric Josun |
| 2011.621 | A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients with Traumatic Brain Injury | Prof. POON Wai Sang |
| 2011.029 | A Randomized, Double-Blind, Placebo-controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment | Dr. Ozaki Risa |
| 2012.333 | A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture | Dr Liu Po Lung Paul |
| 2013.293 | A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy | Dr. OZAKI Risa |
| 2014.055 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | Dr. LAU Alexander Yuk Lun |
| 2004.099 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of the Efficacy and Safety of Tegaserod (6mg b.I.d.), Administered Orally for 12 Weeks, in Male Patients with Chronic Constipation | Dr. Wu Che Yuen Justin |
| 2012.479 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. LEE Alex Pui Wai |
| 2012.474 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. WONG Samuel |
| 2012.480 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. OZAKI Risa |
| 2012.488 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. TSANG Chiu Chi |
| 2012.489 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2019.039 | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in Asian Subjects (≥16 to 80 years of age) with partial seizures with or without secondary generalization |
Dr. LEUNG Ho Wan 梁浩雲醫生 |
| 2011.181 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (_16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES | Professor Patrick Kwan |
| 2005.272 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects (SB-767905/008) | Prof. Gin Tony |
| 2005.253 | A Randomized, Double-blind, Placebo-Controlled, Multicentre Phase 3 Study to Evaluate the Long-term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain | Prof. Gin Tony |
| 2017.612 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD) |
Prof. MOK Chung Tong 莫仲棠 |
| 2007.025 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) | Dr. Chan Hok Sum |
| 2002.179 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing The Rate of Decline of Lung Function with Tiotropium 18mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease(COPD) | Prof. Hui Shu Cheong David |
| 2002.013 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Pros. Study to Evaluate the Effect of a Herbal Preparation With Compound Formula of Danshen and Radix Puerariae as Cardiovascular Tonic in Cardiac Patient | Prof. Woo Kam Sang |
| 2001.489 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of The Therapeutic Effect And Safety Of A Traditional Chinese Medicine (TCM) For Atopic Dermatitis In Children | Prof. HON Ellis Kam Lun |
| 2012.481 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome | Prof. YAN Bryan Ping Yen |
| 2018.122 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneously Administered Tafoxiparin as an Adjuvant to Induction Therapy in Term Pregnant, Nulliparous Women with an unripe cervix |
Prof. LEUNG Tak Yeung 梁德楊教授 |
| 2021.566 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease | Prof. SZETO Cheuk Chun |
| 2009.111 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared with Placebo in Subjects with Type 2 Diabetes Mellitus | Dr. Chow C.C. Francis |
| 2010.200 | A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy | Prof. Tomlinson Brian |
| 2008.414 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects with Partial Onset Seizures, Followed by an Open-Label Extension Study | Prof. Kwan Patrick |
| 2006.319 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ -333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study | Dr. Kwan Patrick |
| 2015.547 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care |
Prof. MA Ronald Ching Wan 馬青雲 |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2003.398 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum | Prof. Ma Buig Yue Brigette |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2006.158 | A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300mg and 900mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients with A History of Renal Disease | Prof. Li Kwok Ming Edmund |
| 2005.110 | A Randomized, Double-blind, Two-arms Placebo-controlled, Parallel-group, Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdoninally Obese Patients | Prof. Brian Tomlinson |
| 2014.222 | A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Effectiveness of Atorvastatin in Patients with Chronic Subdural Haematoma | Prof. POON Wai Sang |
| 2017.327 | A randomized, double-masked, clinical trial comparing extended vs standard endonasal dacryocystorhinostomy (ExStEND) for primary acquired nasolacrimal duct obstruction |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2009.389 | A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema | Dr Lee Yau Wing Vincent |
| 2020.187 | A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration |
Dr. BRELÉN Mårten 柏倫 |
| 2008.086 | A Randomized, International, Double-Blinded (With In-House Blinding), Controlled with GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16-to 26-Year-Old Women | Prof. CHEUNG Tak Hong |
| 2015.689 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
Prof. YEO Winnie 楊明明 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2001.233 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow C.C. Francis |
| 2002.328 | A Randomized, Multi-centre, Double-blind, Double-dummy, Parallel Group Trial of Two Doses of NNC 61-0029 in Combination with Glibenclamide Versus Glibenclamide Monotherapy and Versus Combination Therapy of Glibenclamide and Metformin in the Treatment of Subjects with Type 2 Diabetes | Dr. Chow Chun Chung Francis |
| 2008.248 | A Randomized, Multicenter Phase II Study to Explore Whether Biomarkers Correlate with Treatment Outcome in Chemo-Na・e Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer, Who Receive Treatment with Bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in Addition to Carboplatin-based Chemotherapy (Gemcitabine or Paclitaxel) | Professor Mok Tony |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof SZETO Cheuk Chun 司徒卓俊 |
| 2024.271 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301) | Dr. LI Molly Siu Ching |
Page 39 of 254.